Cancer Immunology • Developmental Therapeutics • Phase I trials • Genitourinary Oncology • Tweets are my own & not medical advice
May 29, 2020 • 6 tweets • 4 min read
Years ago we discovered that FGFR3 alterations are linked with a non-T cell-inflamed immune microenvironment in urothelial #BladderCancer#blcsm (1/6) cancerimmunolres.aacrjournals.org/content/early/…
This finding was replicated in other data sets and suggested that FGFR3-active tumors may be less likely to respond to anti-PD1/L1 #Immunotherapy. It provided a strong rationale for combining FGFR inhibitors with anti-PD-L1 immunotherapy. (2/6)